Efficacy of meropenem and amikacin combination therapy against carbapenemase-producing Klebsiella pneumoniae mouse model of pneumonia.
暂无分享,去创建一个
[1] Taishi Tsubouchi,et al. Molecular and epidemiological analysis of IMP-1 metallo-β-lactamase-producing Klebsiella pneumoniae in a tertiary care hospital in Japan. , 2019, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[2] A. Oliver,et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. , 2017, The Lancet. Infectious diseases.
[3] S. Rittenhouse,et al. A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii , 2017, Journal of visualized experiments : JoVE.
[4] M. Bassetti,et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. , 2015, The Journal of antimicrobial chemotherapy.
[5] B. Gu,et al. Epidemiology of carbapenem resistant Enterobacteriaceae (CRE) during 2000-2012 in Asia. , 2015, Journal of thoracic disease.
[6] N. Kaku,et al. In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[7] M. Niederman,et al. A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] H. Saka,et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. , 2013, American journal of respiratory and critical care medicine.
[9] V. Tam,et al. Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. , 2013, The Journal of infectious diseases.
[10] R. Bonomo,et al. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. , 2013, Diagnostic microbiology and infectious disease.
[11] Y. Carmeli,et al. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[12] G. Daikos,et al. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[13] K. Kishi,et al. Clinical features of healthcare‐associated pneumonia (HCAP) in a Japanese community hospital: Comparisons among nursing home‐acquired pneumonia (NHAP), HCAP other than NHAP, and community‐acquired pneumonia , 2011, Respirology.
[14] J. Le,et al. In Vitro Activity of Carbapenems Alone and in Combination With Amikacin Against KPC-Producing Klebsiella Pneumoniae , 2011, Journal of clinical medicine research.
[15] N Woodford,et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. , 2011, The Journal of antimicrobial chemotherapy.
[16] Y. Chuang,et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. , 2010, Diagnostic microbiology and infectious disease.
[17] K. Bush,et al. Hydrolysis and Inhibition Profiles of β-Lactamases from Molecular Classes A to D with Doripenem, Imipenem, and Meropenem , 2009, Antimicrobial Agents and Chemotherapy.
[18] J. Patel,et al. Fatal cross infection by carbapenem‐resistant Klebsiella in two liver transplant recipients , 2009, Transplant infectious disease : an official journal of the Transplantation Society.
[19] K. Tateda,et al. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. , 2009, The Journal of antimicrobial chemotherapy.
[20] Leonard Leibovici,et al. β lactam monotherapy versus β lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials , 2004, BMJ : British Medical Journal.
[21] W. Craig,et al. Animal model pharmacokinetics and pharmacodynamics: a critical review. , 2002, International journal of antimicrobial agents.
[22] A. Levin,et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] V. Yu,et al. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. , 1999, International journal of antimicrobial agents.
[24] J. Pechère,et al. Efficacy of different dosing schedules of tobramycin for treating a murine Klebsiella pneumoniae bronchopneumonia. , 1987, The Journal of antimicrobial chemotherapy.